Intravascular ultrasound startup Evident Vascular announced today that it launched with a $35 million Series A financing round.
San Jose, California-based Evident Vascular develops an IVUS platform leveraging artificial intelligence (AI). It enables both superior imaging and streamlined workflows.
The company’s launch came with the $35 million in funding from Vensana Capital. Managing Partner Dr. Justin Klein said in a news release that the impetus to launch Evident came from Vensana’s experience in the vascular space. He added that IVUS “is ripe for innovation,” with Evident Vascular addressing a critical need in the market.
IVUS, a transcatheter intravascular imaging technique, acquires images from inside blood vessels. It evaluates vascular disease and guides interventional treatment. According to Vensana Principal Cynthia Yee, the space has seen significant advances in peripheral vascular disease treatments. However, she sees a lag in the diagnostic tools needed to accurately and appropriately guide therapy delivery.
“We see a tremendous opportunity to create a next-generation IVUS platform that addresses the needs of vascular interventionalists, and we are excited to be partnering with an outstanding team to launch Evident Vascular,” Yee said.
According to Howard Rosen, Evident Vascular CEO and co-founder, Shortcomings in image quality, interpretation and workflow have stunted IVUS. However, he believes in its clinical benefit despite the “minimal innovation to address these limitations.”
“Along with my co-founders, Chief Technology Officer Patrick Phillips and Chief Product Officer Danielo Piazza, our team is pioneering the future of intravascular imaging with a platform optimized for peripheral vascular procedures that will enable improved image interpretation guidance, and ease of use enhancements throughout the clinical workflow,” Rosen said.
